Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Softbank Group CORP. trimmed its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 13.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,541,190 shares of the company's stock after selling 1,005,726 shares during the period. Neumora Therapeutics accounts for approximately 0.3% of Softbank Group CORP.'s portfolio, making the stock its 12th largest holding. Softbank Group CORP. owned 4.05% of Neumora Therapeutics worth $69,337,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in Neumora Therapeutics by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company's stock valued at $851,000 after buying an additional 1,629 shares in the last quarter. SkyOak Wealth LLC grew its position in shares of Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company's stock valued at $212,000 after purchasing an additional 5,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $61,000. Charles Schwab Investment Management Inc. raised its stake in shares of Neumora Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company's stock valued at $7,464,000 after purchasing an additional 5,899 shares during the period. Finally, PNC Financial Services Group Inc. bought a new position in Neumora Therapeutics in the 4th quarter worth about $64,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on NMRA shares. Guggenheim lowered shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, March 7th. Bank of America restated an "underperform" rating and set a $1.00 price target (down from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Stifel Nicolaus cut Neumora Therapeutics from a "buy" rating to a "hold" rating and reduced their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. Finally, HC Wainwright decreased their target price on Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Neumora Therapeutics presently has an average rating of "Hold" and an average target price of $9.29.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA traded down $0.01 during trading hours on Monday, reaching $0.69. The company's stock had a trading volume of 1,226,451 shares, compared to its average volume of 1,507,028. The firm has a market capitalization of $111.69 million, a price-to-earnings ratio of -0.37 and a beta of 2.96. The firm has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $4.24. Neumora Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.02). Equities analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.